Acanthosis nigricans is a cutaneous finding characterized by brown-to-black, velvety hyperpigmentation of the skin, most often affecting body folds such as the posterior neck, axillae, groin and umbilicus.
Drug-induced AN may improve after reduction or discontinuation of the causative medication when clinically appropriate. Reported associations include systemic corticosteroids, high-dose nicotinic acid and certain hormonal therapies. Sudden onset, rapid progression or mucosal involvement have been described in malignant forms and may prompt further evaluation. Procedural therapies generally require specialised equipment, and availability and cost may limit use.
Systemic therapies
Because many cases of AN are associated with metabolic dysfunction, improvement in weight or insulin sensitivity may coincide with changes in the skin. Metformin, which is widely used for insulin resistance and type 2 diabetes, has been reported in case series and observational studies to coincide with improvement in AN; however, high-quality randomized trials with AN as a primary outcome are not available.
Glucagon-like peptide-1 (GLP-1) receptor agonists, used for obesity and diabetes, have also been associated with improvement in some individuals with AN in observational reports, likely secondary to changes in metabolic status. These medications are not used specifically to treat AN, and evidence remains indirect.
Prognosis
The prognosis depends on the underlying cause. Obesity- and insulin resistance–related forms often improve with weight loss and metabolic control. Drug-induced cases typically resolve with withdrawal of the causative agent. Hereditary variants may persist. Malignancy-associated acanthosis nigricans may regress following tumour treatment.
<!-- JOURNAL ARTICLES -->
<!-- WEB SOURCES -->